U.S. Capital Wealth Advisors LLC Sells 5,753 Shares of Kenvue Inc. (NYSE:KVUE)

U.S. Capital Wealth Advisors LLC cut its holdings in Kenvue Inc. (NYSE:KVUE) by 16.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,144 shares of the company’s stock after selling 5,753 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Kenvue were worth $548,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Manchester Capital Management LLC boosted its holdings in Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after acquiring an additional 530 shares during the period. Pacific Capital Wealth Advisors Inc. bought a new stake in Kenvue during the fourth quarter valued at about $28,000. Mather Group LLC. bought a new stake in Kenvue during the first quarter valued at about $28,000. Oakworth Capital Inc. bought a new stake in Kenvue during the first quarter valued at about $31,000. Finally, Riverview Trust Co bought a new stake in Kenvue during the first quarter valued at about $33,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Down 1.1 %

Shares of NYSE KVUE traded down $0.23 during midday trading on Friday, reaching $21.02. 20,636,660 shares of the stock were exchanged, compared to its average volume of 19,304,982. The business has a 50-day simple moving average of $18.58 and a two-hundred day simple moving average of $19.43. The company has a market capitalization of $40.25 billion, a price-to-earnings ratio of 27.09, a P/E/G ratio of 2.07 and a beta of 1.38. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.10. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. The company had revenue of $4 billion for the quarter, compared to analysts’ expectations of $3.93 billion. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The business’s quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the firm posted $0.32 earnings per share. As a group, equities research analysts expect that Kenvue Inc. will post 1.13 EPS for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.90%. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date is Wednesday, August 14th. Kenvue’s dividend payout ratio (DPR) is presently 105.13%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on KVUE. HSBC upped their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a research report on Wednesday, May 8th. Citigroup cut their price objective on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday. Sanford C. Bernstein initiated coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective for the company. Finally, UBS Group increased their price target on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.